Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A Plus for plant based products.
https://www.tampabay.com/news/florida-politics/2024/02/03/desantis-fake-meat-cultivated-lab-grown-cattle-industry/
#1 most viewed/listened to podcaster in the world, Joe Rogan chatted Cbd and hemp regulation today with potential Vp candidate Tulsi Gabbard. Hemp talk 5mins-25mins of the link below.
Dive into the world of CBN with our Reserve Sleep products, backed by the comprehensive review.
https://www.pluscbdoil.com/cbd-products/cbd-gummies/reserve-collection-sleep-gummies.html
https://www.sciencedirect.com/science/article/pii/S0926669024003364
The June 4 meeting of the National Center for Complementary and Integrative Health (NCCIH) will convene dozens of NIH-funded researchers studying the pain-relieving properties of compounds in cannabis, and it will also feature a talk by officials at the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA) and National Institute on Drug Abuse (NIDA) on cannabinoid research.
The event marks the final meeting of a group of investigators “who have been conducting NCCIH-supported projects on the mechanisms underlying the analgesic properties of minor cannabinoids and terpenes,” according to a blog from Inna Belfer, an NCCIH Deputy Branch Chief.
https://www.marijuanamoment.net/dea-fda-and-other-agencies-to-discuss-marijuanas-potential-to-treat-pain-at-upcoming-federal-research-meeting/
It was nice to jump in and get the buys going. Who bought 400,000 shares at $5.00 close to the closing and the 100,000 ?
“ Back in January, Tilray CEO Simon Irwin told the Wall Street Journal that Tilray would seek and be able to enter the U.S. "pretty quickly" upon rescheduling, either organically entering the U.S. or by acquiring another cannabis company. And while Cronos only sells cannabis in Canada, Germany, and Israel today, it's also 45% owned by cigarette giant Altria. While Cronos actually exited the U.S. CBD business last year and Altria has considered selling Cronos, one has to think Altria may have plans to attempt a U.S. entry for this subsidiary in light of rescheduling.”
https://finance.yahoo.com/news/why-cannabis-companies-tilray-canopy-201500541.html
https://mjbizdaily.com/cronos-pulls-plug-on-us-hemp-and-cbd-operations/
“ So the fact that CBD remains tied to marijuana in the DEA’s mind might turn out not to be a problem if pot as a whole ends up legal. In the meantime, there will be other products to feed DEA drug scheduling debates. Have you heard about the controversy over scheduling kratom? But therein hangs another tale.”
https://www.cbdmd.com/blogs/posts/is-cbd-oil-legal-a-look-at-dea-drug-scheduling
US drug control agency will move to reclassify marijuana in a historic shift
The U.S. Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug, The Associated Press has learned, a historic shift to generations of American drug policy that could have wide ripple-effects across the country.
The DEA’s proposal, which still must be reviewed by the White House Office of Management and Budget, would recognize the medical uses of cannabis and acknowledge it has less potential for abuse than some of the nation’s most dangerous drugs. However, it would not legalize marijuana outright for recreational use.
The agency’s move, confirmed to the AP on Tuesday by five people familiar with the matter who spoke on the condition of anonymity to discuss the sensitive regulatory review, clears the last significant regulatory hurdle before the agency’s biggest policy change in over 50 years can take effect.
Once OMB signs off, the DEA will take public comment on the plan to move marijuana from its current classification as a Schedule I drug, alongside heroin and LSD. It moves pot to Schedule III, alongside ketamine and some anabolic steroids, following a recommendation from the federal Health and Human Services Department. After the public-comment period the agency would publish the final rule.
Read more: https://apnews.com/article/marijuana-biden-dea-criminal-justice-pot-f833a8dae6ceb31a8658a5d65832a3b8
The CVSI Outstanding increased by 693,615 Shares. MJ news by AP just now so I bought 80,800 shares of CVSI @ .03945 My Tilray’s up 26 percent on the news
Here is my take away-----
This financial stability and increased profitability are reflected in the company's P/E ratio, which stands at an attractive 2.05, suggesting that the stock may be undervalued relative to its earnings.
CV SCIENCES MAINTAINS MARKET LEAD AMID MARKET CHALLENGES.
https://ca.investing.com/news/stock-market-news/earnings-call-cv-sciences-maintains-market-lead-amid-industry-challenges-93CH-3328355
https://finance.yahoo.com/news/cv-sciences-inc-pnk-cvsi-210057560.html
AND:
https://www.procopio.com/cv-sciences-cultured-foods/
https://www.sdbj.com/food/cv-sciences-acquires-polands-cultured-foods/
https://www.prnewswire.com/news-releases/cv-sciences-inc-acquires-cultured-foods-to-enter-plant-based-food-market-opening-door-for-european-distribution-302012400.html
BS Post By Pinocchio Vs The Facts
💲💲💲💲💲💲💲💲💲💲💲💲
CVSI
Profitability
Profit Margin 19.38%
Operating Margin (ttm) -16.79%
Management Effectiveness
Return on Assets (ttm) 20.58%
Return on Equity (ttm) 291.82%
Income Statement
Revenue (ttm) 16M
Revenue Per Share (ttm) 0.10
Quarterly Revenue Growth (yoy) -1.80%
Gross Profit (ttm) N/A
EBITDA 3.85M
Net Income Avi to Common (ttm) 3.1M
Diluted EPS (ttm) 0.0200
Quarterly Earnings Growth (yoy) N/A
Balance Sheet
Total Cash (mrq) 1.32M
Total Cash Per Share (mrq) 0.01
Total Debt (mrq) 442k
Total Debt/Equity (mrq) 15.23%
Current Ratio (mrq) 1.30
Book Value Per Share (mrq) 0.02
Cash Flow Statement
Operating Cash Flow (ttm) 2.25M
Levered Free Cash Flow (ttm) 439.38k
⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️
💩💩💩💩💩💩💩💩💩💩💩💩
CWBHF
Profitability
Profit Margin -37.68%
Operating Margin (ttm) -61.84%
Management Effectiveness
Return on Assets (ttm) -14.72%
Return on Equity (ttm) -35.77%
Income Statement
Revenue (ttm) 63.16M
Revenue Per Share (ttm) 0.41
Quarterly Revenue Growth (yoy) -16.00%
Gross Profit (ttm) N/A
EBITDA -24.9M
Net Income Avi to Common (ttm) -23.8M
Diluted EPS (ttm) -0.1600
Quarterly Earnings Growth (yoy) N/A
Balance Sheet
Total Cash (mrq) 48.99m
Total Cash Per Share (mrq) 0.31
Total Debt (mrq) 60.44M
Total Debt/Equity (mrq) 108.78%
Current Ratio (mrq) 3.31
Book Value Per Share (mrq) 0.36
Cash Flow Statement
Operating Cash Flow (ttm) -15.39M
Levered Free Cash Flow (ttm) -3.89M
Yes, but it's the same out look they been giving for a while now.
"The Company's financial operating results and accumulated deficit, besides other factors, raise substantial doubt about the Company's ability to continue as a going concern. The Company will continue to pursue the actions outlined above, as well as work towards increasing revenue and operating cash flows to meet its future liquidity requirements. However, there can be no assurance that the Company will be successful in any capital-raising efforts that it may undertake, and the failure of the Company to raise additional capital could adversely affect its future operations and viability
✅+PlusCBD RESERVE SLEEP
https://geekspin.co/4-20-gifts/
Followers
|
570
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
82671
|
Created
|
02/27/13
|
Type
|
Free
|
Moderators GE_Jim ap17 Wolf-man jack Thomas@yahoo |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |